http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Deciphera Pharmaceuticals Announces Second Quarter 2023 Financial Results
-
Deciphera Pharmaceuticals Announces Retirement of Daniel L. Flynn, Ph.D., and Appointment of Dashyant Dhanak, Ph.D., as Executive Vice President and Chief Scientific Officer
-
Deciphera Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 9, 2023
-
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society
-
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Deciphera Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
-
Deciphera Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 3, 2023
-
Deciphera Pharmaceuticals to Present at the Stifel Virtual Targeted Oncology Days
-
Deciphera Pharmaceuticals Announces QINLOCK® Included in NCCN Guidelines® for the Treatment of Second-Line GIST Patients and FDA Grants Breakthrough Therapy Designation for QINLOCK in Second-Line GI
-
Deciphera Pharmaceuticals Announces Eight Presentations Highlighting Discovery Research Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
-
Deciphera Pharmaceuticals Announces Completion of Enrollment for Pivotal Phase 3 MOTION Study of Vimseltinib in TGCT
-
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results
-
Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on February 7, 2023
-
Deciphera Pharmaceuticals (DCPH) Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study
-
Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
-
Deciphera Pharmaceuticals (DCPH) Announces Strong Results from ctDNA Analysis from INTRIGUE Phase 3 Study
-
Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company
-
Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations
-
Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit
-
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
-
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results
-
Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022
-
Deciphera Pharmaceuticals (DCPH) Reports Initial Phase 1 Dose Escalation Data for DCC-3116
-
Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022
-
Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO)
-
Deciphera Pharmaceuticals, Inc. to Host Virtual Investor Event Featuring Key Opinion Leaders to Discuss DCC-3116 and Vimseltinib Data Presented at ESMO Congress 2022
-
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Deciphera Pharmaceuticals (DCPH) Reports Publication of INTRIGUE Phase 3 Clinical Study Results
-
Deciphera Pharmaceuticals, Inc. Announces Publication of INTRIGUE Phase 3 Clinical Study Results in Journal of Clinical Oncology
-
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2022 Financial Results
-
Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 4, 2022
-
Deciphera Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Chief Business Officer
-
Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
-
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2022 Financial Results
-
Deciphera Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 4, 2022
-
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Deciphera Pharmaceuticals (DCPH) Prices $150M Share and Warrant Offering at $10/sh
-
Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants
-
Deciphera Pharmaceuticals (DCPH) Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
Deciphera Pharmaceuticals (DCPH) Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting
-
Deciphera Pharmaceuticals Presents Preclinical Data from DCC-3116 Program at the AACR Annual Meeting
-
Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
-
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results
-
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences
-
Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call and Webcast on February 8, 2022
